Holen Sie sich die Stockscreener-App
44.49
0.18%
0.08
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics Insiders Sold US$5.1m Of Shares Suggesting Hesitancy - simplywall.st
HC Wainwright Brokers Reduce Earnings Estimates for PTGX - Defense World
Q2 Earnings Estimate for PTGX Issued By HC Wainwright - Defense World
Protagonist Therapeutics (PTGX) Reveals Promising Phase 3 Trial Results | PTGX Stock News - GuruFocus
Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study - Benzinga
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Johnson & Johnson, Protagonist Therapeutics Say Psoriasis Drug Cleared Skin in Late-Stage Study - marketscreener.com
J&J posts late-stage data for plaque psoriasis drug (JNJ:NYSE) - Seeking Alpha
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting - Stock Titan
10 Best Cancer Stocks to Invest in for Long-Term Gains - Insider Monkey
Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 - ACCESS Newswire
Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance
Protagonist Therapeutics: Strategic Advances and Promising Pipeline Drive Buy Rating - TipRanks
Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience - insights.citeline.com
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Q1 Earnings Snapshot - CTPost
Protagonist Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While A - GuruFocus
Protagonist (PTGX) Reports Q1 Revenue Below Expectations While Advancing Drug Pipeline | PTGX Stock News - GuruFocus
Protagonist Therapeutics, Inc SEC 10-Q Report - TradingView
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | PTGX Stock News - GuruFocus
Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Hits Major Clinical Win: Phase 3 Trial Success Sets Stage for Two FDA Filings in 2025 - Stock Titan
Envestnet Asset Management Inc. Lowers Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Mariner LLC - Defense World
Wells Fargo & Company MN Raises Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Price Target at $65.44 - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Daily Progress: Protagonist Therapeutics Inc (PTGX) Drop -2.84, Closing at 44.85 - DWinneX
Bank of Montreal Can Increases Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 | PTGX Stock News - GuruFocus
Protagonist Therapeutics CFO Sells Shares to Cover Tax Obligation - TradingView
Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025 - Eagle-Tribune
Major Clinical Breakthrough: Rusfertide Phase 3 PV Treatment Data Earns Coveted ASCO Plenary Spot - Stock Titan
Cerity Partners LLC Sells 1,185 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Legal & General Group Plc Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com
Protagonist Therapeutics Reports Granting of Inducement Award | - GuruFocus
Protagonist Therapeutics Reports Granting of Inducement Award - guardonline.com
Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan
Alliancebernstein L.P. Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st
Geode Capital Management LLC Buys 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga
Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):